Clinical characteristics of new psychoactive substances: A multicenter study.
暂无分享,去创建一个
Cheng-Chung Fang | T. Weng | Hsien-Yi Chen | Chih-Chuan Lin | Yu-Jang Su | Yen-Chia Chen | Tse-Hao Chen | Jiun-Hao Yu | Sung-Wei Liu
[1] K. Tusiewicz,et al. Severe poisoning after smoking a mixture of 4-fluoroisobutyryl fentanyl (4-FiBF) and alpha-pyrolidinoisohexaphenone (α-PiHP). , 2021, Journal of forensic and legal medicine.
[2] G. Martinotti,et al. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature , 2021, Medicina.
[3] C. Chaou,et al. Synthetic cathinone poisoning from ingestion of drug-laced “instant coffee packets” in Taiwan , 2021, Human & experimental toxicology.
[4] H. Sumnall,et al. New psychoactive substances: a review and updates , 2020, Therapeutic advances in psychopharmacology.
[5] R. Jalali,et al. Designers Drugs—A New Challenge to Emergency Departments—An Observational Study in Poland , 2020, Medicina.
[6] F. Carvalho,et al. Drinking to death: Hyponatraemia induced by synthetic phenethylamines. , 2020, Drug and alcohol dependence.
[7] H. Peyrière,et al. Use of new psychoactive substances to mimic prescription drugs: the trend in France. , 2020, Neurotoxicology.
[8] Jih-Heng Li,et al. New psychoactive substances in Taiwan: challenges and strategies. , 2020, Current opinion in psychiatry.
[9] Lian-Yu Chen,et al. Characteristics of analytically confirmed illicit substance-using patients in the Emergency Department. , 2020, Journal of the Formosan Medical Association = Taiwan yi zhi.
[10] R. Bruno,et al. New psychoactive substances: challenges for drug surveillance, control, and public health responses , 2019, The Lancet.
[11] J. Lappin,et al. Characteristics and circumstances of death related to new psychoactive stimulants and hallucinogens in Australia. , 2019, Drug and alcohol dependence.
[12] Y. Edel,et al. Prevalence of New Psychoactive Substances (NPS) and conventional drugs of abuse (DOA) in high risk populations from Paris (France) and its suburbs: A cross sectional study by hair testing (2012-2017). , 2019, Drug and alcohol dependence.
[13] Lutea A A de Jong,et al. The risk of emerging new psychoactive substances: The first fatal 3-MeO-PCP intoxication in The Netherlands. , 2019, Journal of forensic and legal medicine.
[14] S. Ikeda,et al. Changes of clinical symptoms in patients with new psychoactive substance (NPS)‐related disorders from fiscal year 2012 to 2014: A study in hospitals specializing in the treatment of addiction , 2019, Neuropsychopharmacology reports.
[15] D. Walther,et al. Analytical quantification, intoxication case series, and pharmacological mechanism of action for N-ethylnorpentylone (N-ethylpentylone or ephylone). , 2018, Drug testing and analysis.
[16] M. Barratt,et al. Typology of new psychoactive substance use among the general Australian population. , 2018, Drug and alcohol dependence.
[17] M. Graw,et al. MDPV in forensic routine cases: Psychotic and aggressive behavior in relation to plasma concentrations. , 2018, Forensic science international.
[18] B. Venhuis,et al. Fatalities, Cerebral Hemorrhage, and Severe Cardiovascular Toxicity After Exposure to the New Psychoactive Substance 4‐Fluoroamphetamine: A Prospective Cohort Study , 2017, Annals of emergency medicine.
[19] S. Lawrie,et al. Characteristics of NPS use in patients admitted to acute psychiatric services in Southeast Scotland: a retrospective cross-sectional analysis following public health interventions , 2017, BMJ Open.
[20] M. van Laar,et al. Characterizing users of new psychoactive substances using psychometric scales for risk-related behavior. , 2017, Addictive behaviors.
[21] U. Bonnet,et al. New Psychoactive Substances (NPS) – a Challenge for the Addiction Treatment Services , 2017, Pharmacopsychiatry.
[22] Laurent Karila,et al. Synthetic Cathinones: A New Public Health Problem , 2015, Current neuropharmacology.
[23] A. Abernethy,et al. Safety of benzodiazepines and opioids in very severe respiratory disease: national prospective study , 2014, BMJ : British Medical Journal.
[24] J. Sheridan,et al. "They're legal so they're safe, right?" What did the legal status of BZP-party pills mean to young people in New Zealand? , 2010, The International journal on drug policy.
[25] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. , 2008, Journal of clinical epidemiology.